Downregulation of E-cadherin was found to be associated with progression, promotion, and poor prognosis, and changes in E-cadherin expression were documented in gastric, prostate, liver, and colon cancers [42,43,44]. The gene discussed is CDH1; the disease is malignant colon neoplasm.